Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model
| Autor: | Alnawaz Rehemtulla, Linda A. Snyder, Craig J. Galbán, Thomas L. Chenevert, Sudha Sud, Kenneth J. Pienta, Chris K. Neeley, Stefan Rozel, Kuei C. Lee, Brian D. Ross, Klaas Nicolay |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
Oncology CA15-3 medicine.medical_specialty medicine.medical_treatment Antineoplastic Agents Bone Neoplasms Docetaxel SDG 3 – Goede gezondheid en welzijn PROSTATE CANCER Biochemistry Article Antibodies Mice Prostate cancer SDG 3 - Good Health and Well-being Internal medicine medicine Animals Humans Effective diffusion coefficient Bioluminescence imaging MACROPHAGES Molecular Biology Chemokine CCL2 Chemotherapy business.industry Monocyte Prostatic Neoplasms Drug Synergism Cell Biology CHEMOTHERAPY medicine.disease Xenograft Model Antitumor Assays Diffusion Magnetic Resonance Imaging medicine.anatomical_structure Apoptosis Immunology Taxoids business medicine.drug |
| Zdroj: | Journal of Cellular Biochemistry, 107(1), 58-64. Wiley-Liss Inc. |
| ISSN: | 1097-4644 0730-2312 |
| DOI: | 10.1002/jcb.22056 |
| Popis: | Metastatic prostate cancer continues to be the second leading cause of cancer death in American men with an estimated 28,660 deaths in 2008. Recently, monocyte chemoattractant protein-1 (MCP-1, CCL2) has been identified as an important factor in the regulation of prostate metastasis. CCL2, shown to attract macrophages to the tumor site, has a direct promotional effect on tumor cell proliferation, migration, and survival. Previous studies have shown that anti-CCL2 antibodies given in combination with docetaxel were able to induce tumor regression in a pre-clinical prostate cancer model. A limitation for evaluating new treatments for metastatic prostate cancer to bone is the inability of imaging to objectively assess response to treatment. Diffusion-weighted MRI (DW-MRI) assesses response to anticancer therapies by quantifying the random (i.e., Brownian) motion of water molecules within the tumor mass, thus identifying cells undergoing apoptosis. We sought to measure the treatment response of prostate cancer in an osseous site to docetaxel, an anti-CCL2 agent, and combination treatments using DW-MRI. Measurements of tumor apparent diffusion coefficient (ADC) values were accomplished over time during a 14-day treatment period and compared to response as measured by bioluminescence imaging and survival studies. The diffusion data provided early predictive evidence of the most effective therapy, with survival data results correlating with the DW-MRI findings. DW-MRI is under active investigation in the pre-clinical and clinical settings to provide a sensitive and quantifiable means for early assessment of cancer treatment outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text